An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Summary

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

Timeline

Start

2019-03-08

Primary completion

2023-08-23

Completion

2023-08-23

Outcome

Outcome not reported

Stopped: “Discontinuation of all bardoxolone chronic kidney disease programs”

Drugs

Indications